Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

Click to increase image sizeClick to decrease image size

Acknowledgements

We also want to acknowledge the members of the MSKCC diagnostic molecular laboratory, flow cytometry laboratory, and immunohistochemical stain laboratory for their support in performing the relevant assays.

Disclosure statement

Dr. Arcila has served as a consultant and received honoraria from Invivoscribe, Inc. Dr. Ho has received honoraria from Invivoscribe, Inc. Dr. Roshal has served as a consultant for BD Biosciences, Agios, Celgene, as well as contract research funding for Agios, Roche, BMS, and Bayer. Dr. Dogan has received compensation from Roche, Novartis, Celgene, Seattle Genetics, and Corvus Pharmaceuticals for consulting/advisory activities. Other authors declare no relevant conflict of interest.

Author contribution

P.K. and M.U. contributed equally to writing the manuscript. J.P. and A.K. provided clinical information on the patient and helped in drafting the manuscript. W.X., A.D., M.R., and C.H. interpreted the histology, flow cytometry, and IHC of the marrow biopsies. U.A. and Y.Z. interpreted the cytogenetics testing results including FISH, karyotype and SNP array analyses. M.A., C.M., J.Y., and C.H. interpreted the molecular assays. Q.G., K.N., W.Y., and M.S. provided technical support for the flow cytometry and molecular assays. All authors reviewed and contributed to the manuscript.

Data availability statement

The complete data supporting the findings in this case report are available from the corresponding author upon reasonable request.

Additional information

Funding

This study was supported by the Comprehensive Cancer Center Core Grant [P30 CA008748] at Memorial Sloan-Kettering Cancer Center (MSKCC) from the National Institutes of Health, USA.